Articles tagged with Attenuated Vaccines
A survey by the Annenberg Public Policy Center found that a strong majority of Americans view the MMR vaccine as safe relative to other vaccines. However, the number of people holding this view is below the threshold required for community immunity, which is worrisome.
The Annenberg Public Policy Center survey finds that most American adults are unclear about the dangers of measles and the value of vaccination. The survey also shows a decline in support for MMR vaccination among parents, from 90% in November 2024 to 82% in August 2025.
A recent survey found that only 38% of US adults recommend taking a Covid-19 vaccine during pregnancy, while only 42% believe it is safe. Women aged 18-49 are even less likely to support vaccination, with 36% and 28% respectively, suggesting a decline in vaccination rates among childbearing women.
A recent Annenberg Public Policy Center survey found that 70% of the public supports vaccine requirements for MMR in schools. The percentage increased from 63% in August 2023. The survey also showed that over 7 in 10 U.S. adults support a policy making it mandatory for parents to vaccinate their children against preventable diseases.
A survey of over 1,600 US adults found that most know the negative impacts of smoking and drinking during pregnancy, but uncertainty exists around vaccines and weight gain recommendations. The majority are unsure about recommended vaccines for pregnant individuals, with a notable drop in knowledge since last year.
The FDA has recommended pausing the use of a live attenuated chikungunya virus vaccine over concerns about safety. The vaccine was previously approved for emergency use in areas with outbreaks.
The clinical trial demonstrated that the vaccine was safe and fully attenuated, causing no malaria infections in adults. The vaccine has the potential to achieve unprecedented potency and is designed to align with WHO's goals for malaria elimination.
The MOPEVACLAS vaccine candidate is being tested in a Phase I clinical trial for its safety and immune response in humans. The vaccine targets Lassa fever, a hemorrhagic disease responsible for thousands of deaths worldwide each year.
Researchers have developed strategies for modifying vaccinia virus to enhance its potential as a vaccine vector. By deleting immunomodulatory proteins and using alternative hosts, scientists can create highly attenuated VACV vaccine vectors. This review provides an overview of the progress in VACV-vectored vaccine development.
A live-attenuated vaccine against Lassa virus has been developed and shown to be safe and 100% effective in protecting guinea pigs from the virus. The vaccine was created by modifying the genome of the virus to prevent it from causing disease, making it a promising candidate for future clinical trials.
Researchers at Children's Hospital of Philadelphia found that the rotavirus vaccine is safe for use in NICU babies, with a low risk of transmission and no clinical consequences. The study suggests that giving the vaccine to eligible infants during their hospitalization provides immune benefits that outweigh any risks.
Scientists have developed an experimental vaccine that combines the benefits of both vaccine strategies, using a horsepox virus to confer safety in a single shot. The new vaccine is substantially more attenuated than the vaccinia virus used in existing vaccines, reducing the risk of side effects and triggering systemic infections.
A team of MIT engineers has developed a new computational method for analyzing complex biological systems, including the immune system's response to tuberculosis vaccination. The approach uses probabilistic graphical networks to identify key interactions and mechanisms, shedding light on how vaccines induce immunity.
A phase Ib clinical trial has shown that the MVA-MERS-S vaccine candidate is safe and effective in healthy individuals previously infected with SARS-CoV-2. The vaccine was tested in a placebo-controlled study with no serious vaccine-related side effects, indicating promising results.
A novel two-step vaccination strategy has been developed to combat seasonal flu, pairing an intramuscular injection with a nasal spray of a weakened live-virus. The approach resulted in a strong immune response and reduced shedding of the vaccine candidate from the upper respiratory tract.
Emerging antimicrobial resistance in Salmonella isolates found in retail chicken meat poses a significant threat to public health. The study found a dramatic increase in multidrug-resistant S. Infantis, which has been linked to high levels of antimicrobial resistance and virulence genes.
Researchers at Northwestern University discovered an attenuated virus that can help eliminate cancer in mice and prevent future tumor development. The therapy works by raising 'red flags' on tumors to alert immune cells to attack them.
A new review emphasizes the importance of vaccination in preventing avian influenza spread among humans. The study suggests that a diverse range of vaccine platforms, including inactivated and live attenuated vaccines, as well as emerging alternatives like mRNA vaccines, will be crucial for enhancing pandemic preparedness.
Scientists identified key factors in developing long-lasting immunity against dengue virus through analyzing immune responses to natural infection and vaccines. The study revealed molecular markers that could be used in novel vaccine development.
Scientists have discovered a TB vaccination strategy that prevents lung infection in monkeys infected with SIV, despite the vaccine being contraindicated for people living with HIV. The results show promise for protecting people with HIV against TB, which is the leading cause of death among them.
Scientists have established the effectiveness of vaccines against leishmaniasis in animal studies, revealing specific molecular-level changes in host cells. The vaccines, created using mutated parasites, prompt distinct immune responses in hosts, offering new insights into their mechanisms and potential applications.
Researchers have identified a key protein in SARS-CoV-2 that, when targeted, elicits a robust immune response. A live-attenuated vaccine based on this protein shows promise in preventing disease and offering long-lasting immunity. The approach could target areas of the genome less likely to change with variants.
The Access to Advanced Health Institute has received an $18 million award from the NIH to develop a temperature-stable, single-dose chikungunya RNA vaccine candidate. The vaccine uses innovative RNA platform technology to protect against the virus, which causes debilitating joint and muscle pain in endemic areas.
Scientists studied 470 sera from vaccinated or MPXV-infected individuals to elucidate mechanisms involved in post-infectious immune response. The study revealed the role of complement and analyzed immune responses in vaccinated or infected individuals, with robust levels of anti-MVA antibodies detected after infection or vaccination.
A new live attenuated SARS-CoV-2 vaccine administered through the nose has shown better immunity than injected vaccines in hamster models, reducing transmissibility. The vaccine stimulates local immunity by activating antibody immunoglobulin A and memory T cells, providing early protection against COVID-19.
The CoDe tool enables precise edits to genetic codes, making vaccines safer and more effective. It can also modulate gene expression in small sections, aiding vaccine design and basic research.
Researchers have made a breakthrough in producing infectious Plasmodium falciparum sporozoites without the need for mosquitoes, paving the way for more effective malaria vaccines. This achievement accelerates the ability to study the parasite's biology and develop new tools for vaccine development.
A study of 1,199 US essential and frontline workers found that recent mRNA vaccination with 2 or 3 doses before infection with Delta or Omicron variants was associated with attenuated symptoms and viral load. Vaccination status also influenced duration of illness and medical care seeking.
Researchers create a modified live attenuated mumps virus for delivery, showing it induces stronger immune responses and provides superior protection against SARS-CoV-2. The new vaccine candidate uses a prefusion version of the spike protein and offers potential to enhance MMR childhood vaccine.
Researchers have developed a new live-attenuated influenza A vaccine approach using proteolysis-targeting chimeric (PROTAC) viruses. The approach uses the endogenous ubiquitin-proteasome system of host cells to degrade viral proteins, resulting in sufficiently attenuated but immunogenic vaccines.
A universal leptospirosis vaccine candidate has been developed, providing cross-protection against different species of the Leptospira genus. The attenuated vaccine elicited a wide range of protein-specific antibodies, targeting key proteins critical to the bacteria's survival.
Researchers suggest live attenuated vaccines like MMR can activate immune cells to combat sepsis and lung inflammation associated with COVID-19. A proposed preventive measure could offer a 'no harm, no foul' benefit for vaccinated adults if infected.
A study by ISGlobal reveals that gene expression in peripheral blood cells can predict vaccine-induced protection against malaria. Boosting the immune system before vaccination may improve vaccine efficacy.
Researchers have created a novel vaccine delivery technology using a finger-tip sized patch with tiny needles that penetrate the skin, releasing molecules to prompt immune responses. The technology has shown improved immunogenicity, including cellular immune responses, and potential advantages in ease of fabrication and storage.
A new vaccine against African swine fever (ASFV) has been developed using a seven-gene-deleted virus. The vaccine, HLJ/18-7GD, was found to be safe and effective in pigs, providing long-lasting immunity against the disease. It is also non-pathogenic and does not pose a risk of transmission to other animals.
A Canadian study suggests that vaccinating older adults against shingles is cost-effective, with the Shingrix vaccine providing better protection than Zostavax. The study found that fewer people need to be vaccinated to prevent one case of shingles for the newer vaccine.
The Department of Defense is funding a study on a promising experimental Zika vaccine at Texas Biomedical Research Institute. Researchers are working to develop a vaccine that can protect pregnant women from the virus and its devastating birth defects.
A new live-attenuated Zika vaccine has been successfully developed in mice, offering complete protection against the virus after a single dose. The vaccine's safety profile is promising, with no adverse effects observed in mice compared to other clinically approved vaccines.
Researchers developed new vaccine strains that are effective, stable, and non-infectious, addressing concerns about live virus escape and disease transmission. The new strains are suitable for mass production in the post-eradication world, reducing risk to humans and environment.
A new study develops a live attenuated SARS-CoV vaccine that maintains genetic stability through targeted modifications of the E protein gene. Vaccinated mice show full protection against challenge with virulent SARS-CoV, demonstrating potential as an efficient and safe vaccine.
A new Ebola vaccine has been shown to be highly effective and safe in monkeys, using an experimental platform that primes the immune system with the full complement of viral proteins. The vaccine was developed by researchers at the University of Wisconsin-Madison and may offer a promising alternative to existing vaccines.
A new dengue vaccine candidate, CYD-TDV, has shown moderate protection of 56% against the disease in a phase 3 clinical trial. The vaccine demonstrated high efficacy against three out of four dengue viruses and reduced severe disease and hospitalizations by more than half.
A new test, RapidChek SELECTTM Salmonella, detects Salmonella Typhi shedding in stool with a 10-fold to 1000-fold improvement over traditional methods. This technology assesses the degree and duration of shedding after immunization, ensuring vaccine efficacy and community safety.
Researchers have developed a new approach to speed up vaccine development by identifying immunomodulators like B2, which enhance immune response and even shrink cancerous tumors. This method uses expression library immunization to rapidly screen entire genomes for desired biological functions.
A Montana State University researcher has made significant breakthroughs in developing a live vaccine against genital herpes. The study found that mice vaccinated with a genetically-modified herpes simplex virus type 1 showed no signs of disease after exposure to the wild-type strain.
Researchers developed a gamma-irradiated Listeria monocytogenes vaccine that elicits a strong T-cell response and protects against live challenge. The irradiated bacteria stimulate both adaptive and innate immune systems, providing a promising alternative to traditional vaccines.
A post-exposure vaccine has been shown to protect monkeys against the deadly Marburg virus. Researchers tested the vaccine in a study involving non-human primates and found it to be highly effective in preventing severe symptoms of the disease.
Researchers at Saint Louis University are testing a new, attenuated vaccine against smallpox, which could be administered to individuals with compromised immune systems. The study aims to explore the safety and efficacy of this investigational drug in a broader population.
Researchers have developed a recombinant yeast antifungal vaccine that protects mice from infection with blastomycosis, a deadly yeast infection of the lung. The vaccine uses a live attenuated strain of Blastomyces dermatitidis to stimulate an immune response against the pathogen.
Scientists have developed a live recombinant vaccine that protects against a fungal infection in mice, using recombinant DNA technology. The vaccine is safer than traditional live vaccines and more effective than 'killed' vaccines, offering a promising approach to protect against rising fungal diseases.
The University of Michigan has thoroughly investigated the book 'Darkness in El Dorado' by Patrick Tierney and found that major claims are false. The university confirms that Dr. Neel's medical care was humane and medically appropriate, and the measles outbreak occurred before his arrival.
A DNA-based flu vaccine has shown promising results in a mouse study, generating high levels of neutralizing antibodies and providing protection at a lower dose. The vaccine combines C3d with HA glycoprotein, priming the immune system against influenza.
Researchers at Harvard Medical School are harnessing the longevity of a herpes simplex virus to develop an HIV vaccine. Their live attenuated vaccine has shown promising results in non-human primates, inducing immunity that lasted for months.
The Blueprint for TB Vaccine Development identifies the TB crisis as a global health priority and encourages an international collaborative effort to develop a vaccine. The report details three different vaccine concepts currently being developed: live, attenuated vaccines; subunit vaccines; and naked DNA vaccines.
The nasal spray flu vaccine protected young children against the A/Sydney flu strain with an 86% efficacy rate, reducing disease severity and middle-ear infections. The two-year study showed overall protection of 92% and significant cross-protection against other strains.
A genetically altered vaccine has been approved for commercial use to prevent swine pneumonia, a major cause of production losses in the swine industry. The vaccine, developed by Virginia Tech researcher Thomas Inzana, confers excellent immunity in pigs with minimal side-effects.
A five-year plan aims for 95% vaccination coverage across countries, with $8 million allocated to strengthen surveillance, improve communications, and evaluate activities. Countries at risk have been targeted for special efforts to prevent outbreaks.
A DNA vaccine developed by Emory University researchers protects monkeys against HIV challenge infections, demonstrating a promising step towards an effective AIDS vaccine. The vaccine uses a two-step approach, priming the immune system with a DNA vaccine and followed by booster immunizations with a pox virus.
BioStratum's gene-attenuated virus vaccines protect macaque monkeys against HIV-1-based viruses. The study demonstrates the efficacy of two vaccines in preventing AIDS development in 11 out of 12 monkeys.
The development of a new vaccine is crucial to effectively eliminate tuberculosis (TB) as a global health problem. The ideal vaccine should prevent new infection, protect those already infected from developing active disease, and prevent reinfection in previously infected individuals.